FDA halts Halozyme's pancreatic cancer study

FDA halts Halozyme's pancreatic cancer study

(Reuters) – Halozyme Therapeutics Inc said the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial. The company's shares

9
Like
Save

Comments

Write a comment

*